Evidence map›Paper›PMID 40967996›Full record

ArticleJournal of clinical lipidology

Greater alterations in atherogenic lipids and inflammatory markers in women during type 2 diabetes development and risk of coronary heart disease-Findings from two population-based studies.

Yilin Yoshida, Danting Li, Xiang Li, Anand Rohatgi, Lydia Bazzano, Vivian A Fonseca, Lu Qi, Franck Mauvais-Jarvis

Abstract read
In one paragraph

Article in Journal of clinical lipidology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yilin YoshidaSection of Endocrinology and Metabolism, Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA (Drs Yoshida, Li, Fonseca, and Mauvais-Jarvis); Center of Excellence in Sex-Based Precision Medicine, Tulane University School of Medicine, New Orleans, LA, USA (Drs Yoshida, Fonseca, and Mauvais-Jarvis). Electronic address: yyoshida1@tulane.edu.
Danting LiSection of Endocrinology and Metabolism, Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA (Drs Yoshida, Li, Fonseca, and Mauvais-Jarvis); Department of Biostatistics and Data Science, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA (Dr Li).
Xiang LiDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA (Dr X. Li).
Anand RohatgiDivision of Cardiology, UT Southwestern Medical Center, Dallas, TX, USA (Rohatgi and Mauvais-Jarvis).
Lydia BazzanoDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA (Dr Bazzano).
Vivian A FonsecaSection of Endocrinology and Metabolism, Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA (Drs Yoshida, Li, Fonseca, and Mauvais-Jarvis); Center of Excellence in Sex-Based Precision Medicine, Tulane University School of Medicine, New Orleans, LA, USA (Drs Yoshida, Fonseca, and Mauvais-Jarvis); Southeast Louisiana VA Medical Center, New Orleans, LA, USA (Dr Fonseca).
Lu QiDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA (Dr Bazzano).
Franck Mauvais-JarvisSection of Endocrinology and Metabolism, Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA (Drs Yoshida, Li, Fonseca, and Mauvais-Jarvis); Center of Excellence in Sex-Based Precision Medicine, Tulane University School of Medicine, New Orleans, LA, USA (Drs Yoshida, Fonseca, and Mauvais-Jarvis); Division of Cardiology, UT Southwestern Medical Center, Dallas, TX, USA (Rohatgi and Mauvais-Jarvis).

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI JUDD E SHELLITO · 2012 to 2026
$69.1M
Sex-Based Precision Medicine Research CoreP20GM152305 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI Marie Krousel-Wood, Mark Mondrinos · 2024 to 2026
$8.9M
Targeting the estrogen receptor-α to protect functional β-cell mass in womenR01DK074970 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI Franck Mauvais-Jarvis · 2007 to 2026
$6.0M
Mentoring Patient-Oriented Research in Deep Lipid Phenotyping for Cardiovascular DiseaseK24HL146838 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Anand Kumar Rohatgi · 2019 to 2026
$945k
BLRD VA I01 BX005812NHLBI NIH HHS K24 HL146838NIDDK NIH HHS R01 DK074970NIGMS NIH HHS P20 GM152305NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

backgroundDiabetes confers a greater risk of coronary heart disease (CHD) in women than in men, potentially due to women's antecedent of metabolic risk factors. We examined circulating metabolites and their associations with CHD risk in men and women across glycemic statuses.

methodsWe analyzed data from 97,271 CHD-free UK Biobank participants. Metabolomic profiling was performed by nuclear magnetic resonance (NMR) spectroscopy of baseline plasma samples. We used linear regression models to examine the association between sex and log-transformed metabolites in newly diagnosed type 2 diabetes (T2D), prediabetes, and euglycemia, adjusting for age, race/ethnicity, Townsend deprivation index, income, smoking, alcohol consumption, physical activity, body mass index, and medication use (for diabetes, lipid-lowering, and hypertension). Cox regression models were used to evaluate associations between metabolites and CHD risk (fatal or nonfatal myocardial infarction) stratified by sex and adjusted for the same covariates. We further considered menopausal status, and all analyses were adjusted for false discovery rate. The analyses were replicated in 6199 participants of the Multi-Ethnic Study of Atherosclerosis (MESA) with NMR data.

resultsWith worsening glycemic status, women exhibited significantly higher atherogenic lipid/lipoprotein markers, fatty acids, and glycoprotein acetyls (GlycA) than men, as well as lower albumin and lactate (all P-values <.0001). Sex differences persisted regardless of menopausal status. In adjusted Cox regressions, 1 SD increase in triglyceride (TG), saturated fatty acids (SFA), and GlycA was associated with a greater risk of CHD in women with T2D than men over a 10-year follow-up (hazard ratios 1.2-1.5 in women and 0.9-1.04 in men, P-interaction <.05).

conclusionsWith worsening glycemic status, women exhibit higher levels of atherogenic lipid and inflammatory markers. TG, GlycA, and SFA are more strongly associated with CHD risk in women with T2D than in men.

Indexed as

AtherosclerosisCoronary DiseaseDiabetes Mellitus, Type 2InflammationLipidsAgedBiomarkersFemaleHumansMaleMiddle AgedRisk FactorsBiomarkersLipidsCoronary heart diseaseLipidomicsMetabolomicsSex differencesType 2 diabetes

Identifiers

PMID40967996
PMCPMC13679688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.